Track topics on Twitter Track topics that are important to you
Iridex reported a net loss of $3.1 million, or $0.27 per share, in the third quarter of 2017 compared with a net loss of $0.7 million, or $0.07 per share, in the same time period of 2016, according to a press release.
Revenue grew by 11% from $9.8 million in 2016’s third quarter to $10.9 million.
Operating expenses increased from $5.5 million in the third quarter of 2016 to $7.4 million in the third quarter of 2017, while a loss from operations rose from $1.2 million to $3.1 million.
The company reported cash and cash equivalents of $22.8 million as of Sept. 30.
Original Article: Iridex posts $3.1 million quarterly lossNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...